Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Income from Non-Controlling Interests (2021 - 2023)

Cytek Biosciences' Income from Non-Controlling Interests history spans 3 years, with the latest figure at -$235000.0 for Q1 2023.

  • For Q1 2023, Income from Non-Controlling Interests fell 71.53% year-over-year to -$235000.0; the TTM value through Dec 2023 reached -$46000.0, down 139.66%, while the annual FY2022 figure was -$92000.0, 453.85% down from the prior year.
  • Income from Non-Controlling Interests reached -$235000.0 in Q1 2023 per CTKB's latest filing, down from $189000.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $315000.0 in Q1 2021 to a low of -$315000.0 in Q2 2021.
  • Average Income from Non-Controlling Interests over 3 years is -$11625.0, with a median of -$7000.0 recorded in 2021.
  • The largest YoY upside for Income from Non-Controlling Interests was 626.92% in 2022 against a maximum downside of 143.49% in 2022.
  • A 3-year view of Income from Non-Controlling Interests shows it stood at $26000.0 in 2021, then soared by 626.92% to $189000.0 in 2022, then tumbled by 224.34% to -$235000.0 in 2023.
  • Per Business Quant, the three most recent readings for CTKB's Income from Non-Controlling Interests are -$235000.0 (Q1 2023), $189000.0 (Q4 2022), and -$40000.0 (Q3 2022).